Business Context and Reporting Period
Company: Sana Biotechnology, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: May 11, 2026
Reporting Period: Quarter ended March 31, 2026
Context: The Company issued a press release on May 11, 2026, announcing its financial results for the quarter ended March 31, 2026. The press release is attached as Exhibit 99.1.
Key Financial Metrics
The provided filing text serves as a cover document referencing the press release (Exhibit 99.1) but does not contain the specific financial data within the text itself. Consequently, the following metrics are not available in the source text:
- Revenue: Not provided in filing text.
- Profit/Loss: Not provided in filing text.
- Cash Flow: Not provided in filing text.
- Margins: Not provided in filing text.
- Debt and Liquidity: Not provided in filing text.
Material Changes
The filing text does not provide specific numerical comparisons or descriptions of material changes versus the prior comparable period. Investors must refer to the attached Exhibit 99.1 (Press Release) for this information.
Guidance, Outlook, and Risks
Guidance and Outlook: The filing text does not contain specific guidance or management commentary regarding future performance.
Risks and Contingencies: No specific risks or contingencies are detailed in the provided text.
Unusual Items: No unusual items are described in the provided text.
Important Facts for Investor Verification
- Source of Data: All financial results for the quarter ended March 31, 2026, are contained in the attached Exhibit 99.1 (Press Release), not in the body of this 8-K.
- Legal Status of Information: The information in Item 2.02 and Exhibit 99.1 is furnished and not deemed "filed" under Section 18 of the Exchange Act, nor is it incorporated by reference into other filings unless expressly stated.
- Emerging Growth Company: The Company is identified as an emerging growth company.
- Signatory: The report was signed by Brian Piper, Executive Vice President and Chief Financial Officer.